A1 Transmittal Letter

Dear AHCCCS (Arizona Health Care Cost Containment System),

Thank you for the opportunity to provide a written response and proposal. At InfuCare Rx Inc., providing the management and care to our hemophilia patients is a great honor. With that said, we have created a model of care that provides a "high touch" approach with assigned Care Managers for every patient so our hemophilia patients, combined with our Clinical Care Team can help our patients reach and maintain the highest levels of a quality life as defined by themselves.

Please find for your consideration, the InfuCare Rx Inc ("InfuCare Rx") proposal for AHCCCS Solicitation #YH23-0093, Specialty Pharmacy Services for Anti-Hemophilia and Other Blood Disorder Medication, along with all necessary and supporting documentation. InfuCare Rx has four pharmacy locations which have pharmacy licensure in the state of Arizona. All four hold a current AHCCCS provider number. By way of this proposal, InfuCare Rx is seeking a contract to provide specialty pharmacy services to AHCCCS's hemophilia and other blood disorder members. InfuCare Rx is a national provider specializing in home infusion, which is inclusive of but not limited to blood clotting factor and other supportive medications for its patients suffering from Hemophilia and other bleeding disorders.

Accreditations ensure adherence to consistent and rigorous standards to pharmacies who "demonstrate the highest value in delivering enhanced clinical services." InfuCare Rx's Center of Excellence for Hemophilia is accredited by the two largest independent pharmacy accreditation bodies, Utilization Review Accreditation Commission (URAC®) and the Accreditation Commission for Health Care (ACHC). Our URAC® accreditation status supports the most recent Specialty Pharmacy 4.0 Program. Additionally, all other pharmacy locations are accredited by ACHC. All pharmacy locations operate under the same InfuCare Rx policies and procedures regardless of accreditations they do or do not hold. This ensures that each location will provide the same quality of care for our patients, your members.

Finally, what makes InfuCare Rx unique from other pharmacies is the Center of Excellence (COE) for Hemophilia model which is comprised of a dedicated Clinical Care Team and Care Managers. The Hemophilia Care Team includes professionals with clinical expertise in the management of bleeding disorders and infusion therapies to assist each patient with their individual treatment. These professionals include pharmacists, nurses, and social workers with whom patients develop long-standing relationships. Additionally, the Care Managers who will be assigned to each AHCCCS member will help guide your members through each step of their treatment processes, provides regularly scheduled quality of life assessments as well as personalized educational resources to aid in the development of health habits and routines that yield positive clinical outcomes so the patients always have a dedicated individual they can call with all questions and issues. InfuCare Rx is one of only two specialty pharmacies nationwide that participate in the Bayer Educational Program for Hemophilia and Bleeding disorders. This program provides patients, who voluntarily register, with specific educational material that allows them to better work with their health care provider teams to manage their bleeding disorders. The program also allows patients to develop an even higher level of trust with the InfuCare Rx provider team.

Signature and contact on second page

Upon AHCCCS acceptance of InfuCare Rx's proposal and issuance of a contract to provide services, InfuCare Rx will provide all the services subject to the terms and conditions set forth in the RFP Solicitation #YH23-0093.

The principal contact for the proposal is:

Victoria McDiarmid, VP of Managed Care
PO Box 2578, Secaucus, New Jersey 07096
Telephone: 313-574-1014
Email: vmcdiarmid@infucarerx.com.

Thank you for your consideration of InfuCare Rx's proposal.

Best regards,

Dhara Patel
Dhara Patel (May 31, 2023 15:43 EDT)

Dhara Patel, President

A1 Transmittal Letter

Final Audit Report 2023-05-31

Created:	2023-05-31
By:	Victoria McDiarmid (vmcdiarmid@infucarerx.com)
Status:	Signed
Transaction ID:	CBJCHBCAABAAAJT8AnX-izwc6AMj9_2TjyFsJBDJDKoO

"A1 Transmittal Letter" History

Document created by Victoria McDiarmid (vmcdiarmid@infucarerx.com)
2023-05-31 - 1:06:53 PM GMT

Document emailed to dbpatel@infucarerx.com for signature
2023-05-31 - 1:07:34 PM GMT

Email viewed by dbpatel@infucarerx.com
2023-05-31 - 7:42:49 PM GMT

Signer dbpatel@infucarerx.com entered name at signing as Dhara Patel
2023-05-31 - 7:43:28 PM GMT

Document e-signed by Dhara Patel (dbpatel@infucarerx.com)
Signature Date: 2023-05-31 - 7:43:30 PM GMT - Time Source: server

Agreement completed.
2023-05-31 - 7:43:30 PM GMT

Adobe Acrobat Sign